373824-30-7

Basic information

• Product Name: AKOS BC-0114
• Synonyms: AKOS BC-0114;3-(2-(PYRROLIDIN-1-YL)ETHOXY)ANILINE
• CAS NO: 373824-30-7
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.28
• Mol File: 373824-30-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BC-0114(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BC-0114(373824-30-7)
• EPA Substance Registry System: AKOS BC-0114(373824-30-7)

Safety Data

• Hazardous Substances Data: 373824-30-7(Hazardous Substances Data)

Upstream product

• 92848-18-5 1-[2-(3-nitro-phenoxy)-ethyl]-pyrrolidine 

Downstream Products

• 936845-98-6 {5-[2-(4-methoxy-phenyl)-vinyl]-thiazol-2-yl}-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine 

Relevant articles and documents

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS

Provided herein are pyrrolopyrimidine compounds of Formula (I) wherein R1 is a heteroaryl containing at least one S atom, and optionally substituted on a ring carbon by one, two, or three substituents each independently selected from the group consisting of : halo, hydroxyl, nitro, formyl, formamido, cyano, sulfonyl, carboxy, amino, amido, acylamino, carbamoyl, sulphamoyl, alkyl, alkenyl, CF3, ureido, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, carbaldehyde oxime, N -alkylsulphamoyl, N-alkylcarbamoyl, -OR13R11 or -R13R11; R2 is phenyl or pyridinyl, wherein R2 optionally substituted on a ring carbon by one, two, or three substituents each indenpendently selected from the group consisting of : halo, hydroxyl, cyano, nitro, formyl, formamido, carboxy, sulfonyl, amino, amido, -N- alkyl -amino, carbamoyl, sulphamoyl, CF3, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, N-alkylsulphamoyl, N-alkylcarbamoyl, -OR11, -OR12R11, or -R12R11; and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

Metasubstituted thiazolidinones, their manufacture and use as a drug

This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.